#USA #Barcelona #Clinical Trials #Data Quality #Veeva DQS

Veeva DQS: Pioneering Data Quality Management in Clinical Trials

Veeva Systems has made a significant announcement regarding its Data Quality System (DQS), which has recently processed and refined data for over one million subjects participating in more than 1,000 clinical studies. This notable achievement aims to expedite the availability of data ready for analysis, ultimately enhancing the quality and speed of insights drawn from clinical trials.

In an era where the scale and complexity of clinical trials are on the rise, the management of massive datasets is crucial. Ibrahim Kamstrup-Akkaoui, Vice President at Novo, emphasizes the importance of efficiently handling the growing volume of data generated by clinical research. He states that Veeva DQS effectively organizes, formats, cleans, and readies data for presentation in a manner that optimizes efficiency. The system has generated over 500,000 automated queries, resulting in thousands of hours saved in data reconciliation for clinical centers and sponsors alike.

One of the standout features of Veeva DQS is its capability to automate data workflows. This advancement not only shifts the burden of manual data reconciliation off the shoulders of clinical teams but also allows for faster access to high-quality data. The system efficiently categorizes and visualizes essential data, facilitating risk-based actions across the entire clinical ecosystem.

Furthermore, the integration of risk-based quality management (RBQM) can enhance monitoring procedures, alerting clinical operation teams to critical changes in data, such as protocol deviations. This is achieved through seamless data exchange between Veeva DQS and Veeva CTMS, thereby equipping teams to track, compute, and act upon key risk indicators (KRIs) promptly.

Adding another layer of sophistication, Veeva DQS incorporates artificial intelligence (AI) to expedite the classification of study data. The AI understands the purpose and significance of data elements, enabling the system to generate customized reports, listings, or scripts based on user roles. This personalization further enhances user experience and workflow efficiency.

As the number of data sources and the complexity of clinical protocols continue to expand, Veeva DQS is increasingly relied upon by sponsors and Clinical Research Organizations (CROs) to automate data workflows on a grand scale across studies of varying sizes. Pavel Burmenko, responsible for the Veeva DQS strategy, notes that the system is advancing next-generation data management, combining risk-based reviews with innovative data management practices that elevate data managers to strategic partners in the clinical trial process.

The recently introduced Veeva Study Builder Agent enables users to set up Veeva EDC and Veeva DQS directly from study protocols, promoting a quicker and more consistent study creation process. This development is set to be a focal point at the upcoming Veeva RD and Quality Summit on October 20-21 in Boston, which caters exclusively to life sciences professionals. Attendees can learn more about Veeva DQS and its role in driving clinical data innovation.

Established as the cloud solution for life sciences, Veeva Systems dedicates itself to excellence in product innovation and customer success. With a broad clientele ranging from leading pharmaceutical companies to emerging biotech firms, Veeva is committed to serving the interests of all stakeholders, including customers, employees, shareholders, and the industries it supports. For further information, visit veeva.com/eu.

In conclusion, Veeva DQS’s ability to streamline data management processes results in significant time and cost savings while providing a robust system for clinical trial data quality. As the landscape of clinical research continues to evolve, solutions like Veeva DQS will play an essential role in ensuring that data integrity remains a top priority.